about
Development of Virus like Particle Vaccine and Reporter Assay for Zika Virus.Current views on Zika virus vaccine development.Adjuvant formulations for virus-like particle (VLP) based vaccines.Current trends in Zika vaccine developmentPassive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge.Recombinant Zika Virus Subunits Are Immunogenic and Efficacious in Mice.Structural biology of Zika virus and other flaviviruses.Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development.Zika virus like particles elicit protective antibodies in mice.The immunology of Zika Virus.Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice.Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.Zika Virus Baculovirus-Expressed Virus-Like Particles Induce Neutralizing Antibodies in Mice.Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E proteinZika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse ModelsA Zika virus vaccine expressing premembrane-envelope-NS1 polyproteinZika Virus Vaccine: Progress and ChallengesGeneration of therapeutic antisera for emerging viral infectionsThe Challenges Imposed by Dengue, Zika, and Chikungunya to BrazilZika Virus Vaccines: Challenges and Perspectives
P2860
Q38156855-A5F4B4F1-F1C9-4C86-97CB-4E5D4A92E18AQ38158576-9E43D102-8A61-41FB-A975-88CDF34D935CQ40093469-85DE446C-3815-4970-AB62-B1994223E2D4Q42334787-E1755DEC-557F-4F18-A3BE-3501CF7ED54BQ47263584-089540E5-1F73-4F0D-8163-2C91154F5FFEQ47550067-FD353C66-304F-40B0-870A-E101204B2DEFQ47555436-3C1B4C54-D463-4258-930B-840905AA2A76Q47558305-5DE5998E-2B16-4894-9996-C7BB7D1A3DE1Q48105726-F06271F2-A82A-4025-88A4-A19706CE791CQ51336389-45299555-35AB-47E0-A29C-51DF88BB7295Q51782806-991E7093-43F9-413A-9E5E-3502E651036CQ52334283-88EA4B1F-45B4-445C-B07B-F00385C15E36Q54558196-99239D0F-2300-45AA-9248-CF6A21F7DF7BQ56000963-4BEE6984-D63A-4E6D-86A0-E5D853EA1DA1Q56339878-99CF79B0-78D8-45CD-973D-DE1094EC4A48Q56341869-3B29511F-DFA5-4E85-A4A9-BAAC37A35354Q56347669-1EB7BDCE-AD8A-4214-B345-CA4CCC84F6C3Q57483199-70E24431-F2E9-4336-985F-8F1F4D84970DQ58698393-153E62E8-35AA-4C27-A6B4-EC023507480CQ58742686-2AB53430-C8A2-4286-8F19-EF967A6C8616
P2860
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Zika virus-like particle (VLP) based vaccine
@ast
Zika virus-like particle (VLP) based vaccine
@en
type
label
Zika virus-like particle (VLP) based vaccine
@ast
Zika virus-like particle (VLP) based vaccine
@en
altLabel
Zika virus-like particle (VLP) based vaccine
@en
prefLabel
Zika virus-like particle (VLP) based vaccine
@ast
Zika virus-like particle (VLP) based vaccine
@en
P2093
P2860
P1476
Zika virus-like particle (VLP) based vaccine
@en
P2093
Alexandra Alimova
George R Martin
Hélène Boigard
Paul Gottlieb
P2860
P304
P356
10.1371/JOURNAL.PNTD.0005608
P407
P577
2017-05-08T00:00:00Z